Related Experiment Video
Updated: Feb 24, 2026

Peptide-based Identification of Functional Motifs and their Binding Partners
Published on: June 30, 2013
HIV-1 Nef-induced cardiotoxicity through dysregulation of autophagy
Manish K Gupta1, Rafal Kaminski1, Brian Mullen1
1Department of Neuroscience, Center for Neurovirology and Comprehensive NeuroAIDS Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Insights
HIV-1 Nef protein impairs cardiomyocyte health by disrupting autophagy, a key cellular cleaning process. This dysfunction contributes to heart disease in HIV patients, but rapamycin treatment showed promise in reversing these effects.
Area of Science:
- Cardiovascular Biology
- Virology
- Cellular Biology
Background:
- Cardiovascular disease is a major complication in HIV-1 patients, irrespective of viral load.
- The exact cause of HIV-1-associated cardiomyopathy remains unclear, with no direct viral replication in heart cells.
- Extracellular release of HIV-1 Nef protein from infected CD4+ T cells is suspected to impact heart tissue.
Purpose of the Study:
- To investigate the impact of HIV-1 Nef on protein quality control (PQC) and autophagy in cardiomyocytes.
- To understand the molecular mechanisms by which Nef affects cardiomyocyte homeostasis.
Main Methods:
- Detection of Nef in patient serum and heart tissue.
- Cell and molecular biology techniques to study Nef's effects on cardiomyocytes.
- Analysis of PQC pathways and autophagy flux, including interactions with Beclin 1/Rab7 and TFEB localization.
Main Results:
- HIV-1 Nef inhibits autophagy flux, leading to cardiomyocyte cytotoxicity and death.
- Nef interferes with autophagosome maturation by affecting Beclin 1/Rab7 interactions and TFEB-mediated lysosome regulation.
- Rapamycin treatment successfully reversed the detrimental effects of Nef on cardiomyocytes.
Conclusions:
- HIV-1 Nef-induced inhibition of cellular PQC and autophagy is a potential mechanism driving HIV-associated cardiomyopathy.
- Targeting autophagy may offer a therapeutic strategy for managing heart disease in HIV-1 patients.
Abstract:
Cardiovascular disease is a leading cause of co-morbidity in HIV-1 positive patients, even those in whom plasma virus levels are well-controlled. The pathogenic mechanism of HIV-1-associated cardiomyopathy is unknown, but has been presumed to be mediated indirectly, owing to the absence of productive HIV-1 replication in cardiomyocytes. We sought to investigate the effect of the HIV-1 auxiliary protein, Nef, which is suspected of extracellular release by infected CD4+ T cells on protein quality control and autophagy in cardiomyocytes. After detection of Nef in the serum of HIV-1 positive patients and the accumulation of this protein in human and primate heart tissue from HIV-1/SIV-infected cells we employed cell and molecular biology approaches to investigate the effect of Nef on cardiomyocyte-homeostasis by concentrating on protein quality control (PQC) pathway and autophagy. We found that HIV-1 Nef-mediated inhibition of autophagy flux leads to cytotoxicity and death of cardiomyocytes. Nef compromises autophagy at the maturation stage of autophagosomes by interacting with Beclin 1/Rab7 and dysregulating TFEB localization and cellular lysosome content. These effects were reversed by rapamycin treatment. Our results indicate that HIV-1 Nef-mediated inhibition of cellular PQC is one possible mechanism involved in the development of HIV-associated cardiomyopathy.
Related Concept Videos
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Pathophysiology of Heart Failure
Delivery Pathways to the Lysosome
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy

